Ionis Pharmaceuticals

IONS

Market cap $12.4B

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invente.

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patients High Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA).

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.

Ionis Pharmaceuticals (NASDAQ:IONS) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high, currently trading near $72.70.

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026. "Alexander disease is a devastating condition,.

Ionis Pharmaceuticals (IONS) projects $2B+ peak revenue for Olezarsen, but I believe this is highly conservative given the U.S. addressable market. Olezarsen demonstrated a 72% reduction in triglycerides and 85% reduction in acute pancreatitis events, with no comparable competition in efficacy. Current guidance assumes reaching only 10% of the 1M high-risk U.S. sHTG patients, with pricing likely near $20,000 per patient annually.

Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript

Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript